Riskpilot← Back to searchSign inGet full accessCarcinoQuant AB
ABActiveOrg 5591684518Förändringens Gata 10Research and experimental development on natural sciences and engineering · NACE 7210Est. 20180 employees
Revenue 2024
SEK 0
EBITDA margin
—
+71% vs 2023
Equity ratio
89.6%
Financial strength
Net profit 2024
SEK 18K
+357% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -2K | +71% |
| Net profit | SEK 18K | +357% |
| Total assets | SEK 48K | +60% |
| Equity | SEK 43K | +72% |
| Employees | 0 | — |
Legal name
CarcinoQuant AB
Org number
5591684518
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
20 augusti 2018
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Bolaget ska utveckla och sälja metoder för läkemedelsutveckling och diagnostik inom sjuk- och hälsovårdsbranschen.
Address
Förändringens Gata 10
Email
anders.strigen@antarosmedical.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — | — |
| EBITDA | −6 | −8 | −3 | −1 | −7 | −2 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 |
| EBIT | −6 | −8 | −3 | −1 | −7 | −2 |
| Net financials | — | — | — | — | — | — |
| Profit before tax | −6 | −8 | −3 | −1 | −7 | 18 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −6 | −8 | −3 | −1 | −7 | 18 |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Total assets | 49 | 41 | 39 | 37 | 30 | 48 |
| Equity | 44 | 36 | 34 | 32 | 25 | 43 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 5 | 5 | 5 | 5 | 5 | 5 |
| Total debt | 5 | 5 | 5 | 5 | 5 | 5 |
EBITDA margin
-200000.0%
This company
15.8%
Market median
-1265923% vs market
20192024
Equity ratio
89.6%
This company
38.2%
Market median
+135% vs market
20192024
Return on equity
41.9%
This company
18.4%
Market median
+128% vs market
20192024
Net profit margin
1800000.0%
This company
8.1%
Market median
+22222122% vs market
20192024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20192024
Debt / equity
0.12×
This company
0.62×
Market median
+81% vs market
20192024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2018-08-01 – 2019-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
MF Chief Auditor | Chief Auditor | 2022 | — | — |
ST Chief Auditor | Chief Auditor | 2021 | — | — |
JE | Audit | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Chairman | 2020 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Antaros Invest AB | Company | 100.0% | 100.0% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of CarcinoQuant AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Magnus Fjellman | Chief Auditor | 0 companies |
| Sven Tiberiu Cristea | Chief Auditor | 0 companies |
| John Erik Andreas Österlund | Audit | 0 companies |
| Christina Elisabeth Abrahamsson | Board of Directors | 0 companies |
| Lars Olof Mikael Johansson | Board of Directors | 0 companies |
| Lars Anders Strigén | Board of Directors | 0 companies |
| Sven Wenzel Johannes Hulthe | Chairman | 0 companies |